ClinicalTrials.gg
RecruitingNCT07122167Updated Sep 12, 2025

Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions

An interventional study of Peripheral Drug-eluting Stent System in Peripheral Arterial Disease, sponsored by MDCECRO LLC. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by MDCECRO LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Planned enrollment
15th of 28
153 · median 220
Started
2025
with 4 others
No phase
16 of 31
4 open now
Registered
29th of 31
by date

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 15th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, and was the 29th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be followed at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • peripheral arterial disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Aged 18 to 80 years, regardless of gender. (2) Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5. (3) Subject (or legal guardian, if applicable) is willing and able to provide consent before to the performance of any study specific tests or procedures, has signed the consent form and agrees to attend all required follow-up visits.

Angiographic Inclusion Criteria:

Eligible subjects must meet all of the following angiographic criteria:

  1. Stenotic, restenotic or occlusive lesion(s) located in the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) (i.e., within the P1 segment):

    1. Degree of stenosis ≥70% by visual angiographic assessment.
    2. Vessel diameter ≥4.0 mm and ≤6.5 mm.
    3. Total lesion length (or series of lesions) ≥ 10 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one stent).
    4. Chronic total occlusion with a total lesion length of ≤120 mm.
  2. Patent popliteal and infrapopliteal arteries, with single-vessel runoff or better, defined as at least one of the three vessels remaining patent (i.e., \<50% stenosis) down to the ankle or foot.

Exclusion criteria

Exclusion Criteria:

  • Clinical exclusion criteria:

Subjects will be excluded from the study if any of the following conditions are present:

  1. Pregnant or breastfeeding women, or women/men planning to conceive.
  2. Subjects who have had or are planned for major amputation (at or above the ankle level).
  3. Subjects known to be allergic or intolerant to materials used in the device or treatment drugs, including nitinol, paclitaxel, aspirin, clopidogrel, heparin, rivaroxaban, contrast agents, etc.
  4. Subjects with serum creatinine ≥2.5 mg/dL or currently undergoing dialysis.
  5. Subjects with known, uncorrectable hemorrhagic disorders or severe coagulation dysfunction ( (PT) or activated partial thromboplastin time (aPTT) ≥2 times the , or count \<80×10⁹/L).
  6. Previously stented target lesion/vessel.
  7. Target lesion/vessel previously treated with drug-coated balloon \<12 months prior to enrollment.
  8. Subjects with a of less than 1 year.
  9. Subjects who have received local or systemic thrombolysis treatment within 48 hours prior to enrollment.
  10. Subjects diagnosed with major clinical diseases or unstable conditions within the past 3 months, such as severe heart failure, unstable angina, myocardial infarction, or stroke, severe neurological or psychiatric history, severe infections, gastrointestinal bleeding, or active disseminated intravascular coagulation.
  11. Subjects currently participating in another clinical trial involving drugs or medical devices.
  12. Subjects whom the investigator considers unsuitable for participation in the clinical trial.

Angiographic exclusion criteria:

  1. Presence of aneurysm in the target vessel.
  2. Heavily calcified lesions (Peripheral Arterial Calcium Scoring System [PACSS] grades 3-4).
  3. The target lesion requires the use of plaque excision, laser, or other debulking devices that may damage the vessel intima.
  4. The guidewire cannot pass through the target lesion, or percutaneous transluminal angioplasty (PTA) balloon cannot be used for pre-dilation.
  5. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Other
    Prospective, Multi-center, Single-arm.

    Device: Peripheral Drug-eluting Stent System

Interventions

  • DevicePeripheral Drug-eluting Stent System

    Drug-eluting stents (DES) are increasingly used in the treatment of PAD. These stentsare coated with antiproliferative drugs designed to provide mechanical support within the artery while releasing the drug gradually to reduce the risk of restenosis. Commonly used drugs include paclitaxel, sirolimus, and everolimus, which inhibit vascular smooth muscle cell proliferation, thereby reducing the likelihood of re-occlusion.

06

What researchers measure

Primary outcomes

  1. Primary patency at 12 months post-procedure

    Primary vessel patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤2.4 at the 12-month follow-up visit in the absence of clinically driven TLR or bypass of the target lesion.

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
  • Cardiovascular
    Chrzanów, Chrzanow 32-500, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 18 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 14, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 1, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07122167
Lead sponsor
MDCECRO LLC
Collaborators
Zylox-Tonbridge Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jun 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Qiqing BO, Clinical Operations Manager
Contact
qq.bo@zyloxmedical.com
+86 18610591755

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion